SCHEMBL5430744

SCHEMBL5430744

CCn1cc(C(=O)OCCOC)c(=O)c2cc(CCCN)ccc21

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.53
HPGD P15428 4/20 0.47
ALDH1A1 P00352 4/20 0.47
KDM4E B2RXH2 3/20 0.47
HSD17B10 Q99714 3/20 0.47
TSHR P16473 1/20 0.47
RAB9A P51151 1/20 0.47
MAPK1 P28482 1/20 0.46
KMT2A Q03164 3/20 0.44
MEN1 O00255 2/20 0.44
MAPT P10636 1/20 0.44
THRB P10828 1/20 0.44
POLB P06746 1/20 0.42
TP53 P04637 1/20 0.42
PDE4A P27815 2/20 0.41
PDE4B Q07343 2/20 0.41
PDE4C Q08493 2/20 0.41
PDE4D Q08499 2/20 0.41
CNR2 P34972 2/20 0.41
CNR1 P21554 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5681141 0.93 LMNA (0.54) LMNAHPGDALDH1A1KDM4EHSD17B10
SCHEMBL5444342 0.92 LMNA (0.53) LMNAHPGDALDH1A1KDM4EHSD17B10
SCHEMBL3978265 0.91 LMNA (0.65) LMNAHPGDALDH1A1KDM4EHSD17B10
SCHEMBL5425671 0.88 KMT2A (0.50) LMNAHPGDALDH1A1KDM4EHSD17B10
SCHEMBL5427795 0.87 LMNA (0.53) LMNAHPGDALDH1A1KDM4EHSD17B10
SCHEMBL5437230 0.86 SMN1; SMN2 (0.52) LMNAHPGDALDH1A1KDM4EHSD17B10
SCHEMBL5430704 0.86 LMNA (0.48) LMNAHPGDALDH1A1KDM4EHSD17B10
Trifluoroacetic Acid SCHEMBL4392488 0.85 LMNA (0.59) LMNAHPGDALDH1A1KDM4EHSD17B10
SCHEMBL5441329 0.85 LMNA (0.51) LMNAHPGDALDH1A1KDM4EHSD17B10
SCHEMBL5446001 0.85 LMNA (0.51) LMNAHPGDALDH1A1KDM4EHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070293472-A1 Novel 14 and 15 Membered Ring Compounds GLAXO GROUP LIMITED (GB) 2007-12-20 US disclosed
EP-1628989-B1 NOVEL 14 AND 15 MEMBERED-RING COMPOUNDS GLAXO GROUP LTD (GB) 2006-12-20 EP disclosed
EP-1628989-A1 NOVEL 14 AND 15 MEMBERED-RING COMPOUNDS GLAXO GROUP LIMITED (GB) 2006-03-01 EP disclosed
WO-2004101587-A1 NOVEL 14 AND 15 MEMBERRED-RING COMPOUNDS GLAXO GROUP LIMITED (GB) 2004-11-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070293472-A1 Novel 14 and 15 Membered Ring Compounds IL17A, CYP51A1, IL15 LMNA 4168/4885HPGD 1054/4885ALDH1A1 2338/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.